Page last updated: 2024-11-05

dimethindene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dimethindene is an antihistamine with anticholinergic and antiserotonergic activity. It is used to treat allergic conditions such as hay fever, urticaria, and allergic rhinitis. Dimethindene is a piperidine derivative, and its synthesis involves several steps, including the reaction of 2-chloro-1-(2-pyridyl)ethanone with 1,3-dimethyl-2-imidazolidinone. The compound acts by blocking histamine receptors, preventing the release of histamine and reducing allergic symptoms. Dimethindene is also effective in treating nausea and vomiting. It is studied for its potential use in treating other conditions such as anxiety, depression, and Parkinson's disease. However, it is important to note that dimethindene can cause side effects such as drowsiness, dry mouth, and blurred vision. It is available in various formulations, including tablets, capsules, and syrups. Dimethindene has been used to treat allergies for several decades, but newer antihistamines are now preferred due to their fewer side effects.'

Dimethindene: A histamine H1 antagonist. It is used in hypersensitivity reactions, in rhinitis, for pruritus, and in some common cold remedies. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21855
CHEMBL ID22108
CHEBI ID135222
SCHEMBL ID18759
MeSH IDM0006449

Synonyms (61)

Synonym
pyridine, 2-(1-(2-(2-(dimethylamino)ethyl)inden-3-yl)ethyl)-
1h-indene-2-ethanamine, n,n-dimethyl-3-[1-(2-pyridinyl)ethyl]-
n,n-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1h-inden-2-yl]ethanamine
dimethindene
brn 0489974
einecs 227-083-8
n,n-dimethyl-n-(3-(1-(2-pyridyl)ethyl)-2-indenylethyl)amin
dimetindenum [inn-latin]
dimetindeno [inn-spanish]
2-(1-(2-(2-dimethylaminoethyl)inden-3-yl)ethyl)pyridine
dimethpyrindene
n,n-dimethyl-3-(1-(2-pyridyl)ethyl)inden-2-ethylamin
1h-indene-2-ethanamine, n,n-dimethyl-3-(1-(2-pyridinyl)ethyl)-
dimetindene [inn:ban]
dimethyl{2-[3-(2-pyridylethyl)inden-2-yl]ethyl}amine
forhistal
dimetindene
5636-83-9
n,n-dimethyl-2-[3-[1-(2-pyridyl)ethyl]-1h-inden-2-yl]ethanamine
CHEBI:135222
feniallerg
CHEMBL22108
DB08801
D07853
dimetindene (inn)
cas_91533
nsc_91533
bdbm81452
AKOS015965045
dimetindeno
5-22-11-00123 (beilstein handbook reference)
dimetindenum
unii-661fh77z3p
661fh77z3p ,
FT-0625024
vibrocil
dimetindene [who-dd]
dimethindene [mi]
2-(1-(2-(2-(dimethylamino)ethyl)inden-3-yl)ethyl)pyridine
(+/-)-dimethindene
n,n-dimethyl-3-(1-(2-pyridinyl)ethyl)-1h-indene-2-ethanamine
dimetindene [inn]
3-(.alpha.-(2'-pyridyl)ethyl)-2-(.beta.-dimethylaminoethyl)indene
SCHEMBL18759
n,n-dimethyl-2-(3-[1-(2-pyridinyl)ethyl]-1h-inden-2-yl)ethanamine #
MVMQESMQSYOVGV-UHFFFAOYSA-N
DTXSID9022942
dimethyl(2-{3-[1-(pyridin-2-yl)ethyl]-1h-inden-2-yl}ethyl)amine
dimetinden
(+/-)-dimetahindene
dimethylpyrindene
n,n-dimethyl-2-(3-(1-(pyridin-2-yl)ethyl)-1h-inden-2-yl)ethanamine
Q426070
gtpl10101
mfcd00865676
dimethpyrindene; dimetindene; feniallerg; forhistal
SB82460
EN300-312823
CS-0007739
HY-13710
Z2235811601

Research Excerpts

Overview

Dimethindene is a selective histamine with strong affinity to the H1-receptor. HDimethindenes maleate is a well known H1,receptor antagonist.

ExcerptReferenceRelevance
"Dimethindene is a selective histamine H"( Green Solvents for Eco-Friendly Synthesis of Dimethindene: A Forward-Looking Approach.
Alario, C; Capriati, V; García-Álvarez, J; Perna, FM; Quivelli, AF; Rossi, FV; Sannicolò, F; Vitale, P, 2022
)
2.42
"Dimethindene maleate is a well known H1-receptor antagonist with strong affinity to the H1-receptor. "( Effect-kinetic characterization of dimethindene maleate following oral administration (Fenistil, Tropfen).
Geissler, H; Hennings, G; Lukas, H; Rehn, D; Schuster, O, 1990
)
2

Toxicity

ExcerptReferenceRelevance
" In Hungary approximately 200,000 boxes are sold yearly from this product, which is mainly used for treatment of symptoms associated with allergic diseases (urticaria, itch, hay fever) The aim of the present study was to gather information with the help of medical doctors about the indications, efficacy and primarily the safety of use, observed side effects and frequency of adverse events associated with this product."( [Prescription and safety of dimethindene maleate micropellet capsules in Hungary].
Mikó, P, 2004
)
0.62
" Unexpected, new adverse events were not observed during the study."( [Prescription and safety of dimethindene maleate micropellet capsules in Hungary].
Mikó, P, 2004
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters (AUC, t1/2, CLs, Vd and F) were calculated using the clearance approach."( Pharmacokinetics of dimetindene after intravenous and oral administration to healthy volunteers.
Althaus, MA; Arnera, V; Balant, LP; Llull, JB; Wellman, M; Wermeille, M, 1990
)
0.28
" One of these compounds, 10a, showed equivalent efficacy in a rat EEG/EMG model to a previously identified clinical candidate and a potentially superior pharmacokinetic profile as determined from a human microdose study."( Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.
Beaton, G; Bradbury, MJ; Coon, T; Crowe, PD; Hernandez, LM; Hoare, SR; Huang, C; Jalali, K; Li, BF; Madan, A; Malany, S; Marinkovic, D; Moree, WJ; Petroski, RE; Sacaan, A; Tucci, FC; Wang, H; Wen, J; Yang, C; Yu, J; Zamani-Kord, S, 2010
)
0.36

Dosage Studied

Rats dosed with 30 and 60 mg/kg (R)-dimethindene showed 42% and 67% occupancy of central H1 receptors, respectively.

ExcerptRelevanceReference
" Dose-response relationships were obscured by a large variability in response of individual skins."( Effects of chloropyramine, dimethindene and diphenhydramine on transepithelial ion transport: studies in bovine tracheal epithelium and frog skin.
Durand, J; Durand-Arczynska, W; Schoenenweid, F, 1986
)
0.57
"Based on the study results in Hungary in most cases the product is prescribed according to the indications and dosing schedule given in the SPC."( [Prescription and safety of dimethindene maleate micropellet capsules in Hungary].
Mikó, P, 2004
)
0.62
"In Hungary in most cases the product is prescribed according to the indications and dosing schedule given in the current approved Summary of Product Characteristics."( [Prescription and safety of dimethindene maleate micropellet capsules in Hungary].
Mikó, P, 2004
)
0.62
"Capillary isotachophoresis was employed to determine dimethindene in various dosage forms."( [Dimethindene determination in various dosage forms by means of capillary isotachophoresis].
Havránek, E; Kubacák, P; Mikus, P; Valásková, I, 2005
)
1.49
"Capillary isotachophoresis was employed to separate and determine dimethinden enantiomers in various dosage forms."( [Separation of dimetinden enantiomers in drugs by means of capillary isotachophoresis].
Havránek, E; Kubacák, P; Mikus, P; Valásková, I, 2006
)
0.33
" Rats dosed with 30 and 60 mg/kg (R)-dimethindene showed 42% and 67% occupancy of central H1 receptors, respectively."( Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors.
Crowe, PD; Hernandez, LM; Hoare, SR; Malany, S; Smith, WF, 2009
)
0.83
"A stability-indicating high performance liquid chromatography method with diode array detection (HPLC-DAD) was developed and validated for simultaneous determination of phenylephrine hydrochloride (PHR), dimetindene maleate (DMD) and benzalkonium chloride (BZM) in nasal drops and gel dosage forms."( Analytical investigation of ternary mixture of phenylephrine hydrochloride, dimetindene maleate and benzalkonium chloride using validated stability indicating HPLC-DAD method.
Abdel-Khalek, MM; Abdelhamid, AG; Belal, TS; El-Kafrawy, DS, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Dimetindene H1-Antihistamine Action87

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.04470.00000.690210.0000AID142646
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.40740.00000.79519.1201AID142001
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.79430.00000.72926.9183AID142273
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.26300.00000.59729.1201AID141302
Muscarinic acetylcholine receptor M1Mus musculus (house mouse)Ki0.26300.00160.41173.1623AID141302
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.19050.00000.54057.7600AID141590
Histamine H1 receptorRattus norvegicus (Norway rat)Ki0.00070.00071.54406.5000AID87370
Histamine H1 receptorHomo sapiens (human)Ki0.00070.00000.511010.0000AID87370
Histamine H1 receptor Mus musculus (house mouse)Ki0.00070.00071.63885.1250AID87370
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (47)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID142001Affinity for Muscarinic acetylcholine receptor M4 expressed in CHO cells by [3H]NMS displacement.2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Design and pharmacology of quinuclidine derivatives as M2-selective muscarinic receptor ligands.
AID141590Affinity for Muscarinic acetylcholine receptor M3 expressed in CHO cells by [3H]-NMS displacement.2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Design and pharmacology of quinuclidine derivatives as M2-selective muscarinic receptor ligands.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID142273Affinity for Muscarinic acetylcholine receptor M5 expressed in CHO cells by [3H]NMS displacement.2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Design and pharmacology of quinuclidine derivatives as M2-selective muscarinic receptor ligands.
AID87370Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.
AID610131Half life in human2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.
AID142646Affinity for Muscarinic acetylcholine receptor M2 expressed in CHO cells by [3H]NMS displacement.2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Design and pharmacology of quinuclidine derivatives as M2-selective muscarinic receptor ligands.
AID141302Affinity for Muscarinic acetylcholine receptor M1 expressed in CHO cells by [3H]NMS displacement.2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Design and pharmacology of quinuclidine derivatives as M2-selective muscarinic receptor ligands.
AID431646Elimination half life in human at 50 mg, po2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.
AID431645Half life in human2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (203)

TimeframeStudies, This Drug (%)All Drugs %
pre-199095 (46.80)18.7374
1990's57 (28.08)18.2507
2000's27 (13.30)29.6817
2010's17 (8.37)24.3611
2020's7 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.27 (24.57)
Research Supply Index5.57 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index96.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials50 (23.58%)5.53%
Reviews5 (2.36%)6.00%
Case Studies12 (5.66%)4.05%
Observational0 (0.00%)0.25%
Other145 (68.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Placebo Effect in Atopic Dermatitis - Increase the Pharmacological Effect of Itching Caused by Classical Conditioning and Expectancy Processes: A Randomized Controlled Trial [NCT02094287]166 participants (Actual)Interventional2010-09-30Completed
A Randomized, Crossover, Double-Blind Study To Evaluate The Safety Of An Association Of Phenylephrine Hydrochloride 10mg + Acetaminophen 500mg + Dimethindene Maleate 1 Mg Compared To Phenylephrine Hydrochloride 10mg In Healthy Volunteers [NCT01026961]Phase 1/Phase 20 participants (Actual)Interventional2010-09-30Withdrawn(stopped due to Study is no longer required by Brazil health authority.)
A Prospective, Randomized, Investigator-Blind Study to Compare Three Days of Treatment With Paracetamol (500 mg) / Dimethindene Maleate (1 mg) / Phenylephrine Hydrochloride (10 mg) Tablets Versus Paracetamol 500 mg Alone in the Treatment of Nasal Congesti [NCT01448057]Phase 3341 participants (Actual)Interventional2013-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01448057 (2) [back to overview]Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms
NCT01448057 (2) [back to overview]Physician Global Evaluation of Effectiveness on Nasal Symptoms

Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms

Subject will assess Nasal and non Nasal symptoms using a 100 mm Visual Analog Scale for each symptom, 0=no symptoms 100= the worst possible symptoms (NCT01448057)
Timeframe: Day 3

Interventionmm (Mean)
Arm A169.2
Arm B225.3

[back to top]

Physician Global Evaluation of Effectiveness on Nasal Symptoms

"The Physician will measure the reduction of Nasal Symptoms (Nasal Congestion, Sneezing, and Rhinorrhea) on day 2.~Range from 1 to 5 where 1 is excellent and 5 is bad :~1 = excellent : 75% to 100% remission of signs and symptoms 5 = bad : exacerbation of nasal symptoms" (NCT01448057)
Timeframe: Day 2

Interventionscore on a scale (Mean)
Arm A1.9
Arm B2.1

[back to top]